Literature DB >> 16001918

Experimental aspects of the pathogenesis of Robin sequence.

Johannes Schubert1, Heiko Jahn, Markus Berginski.   

Abstract

OBJECTIVE: The Pierre Robin Sequence (PRS) is a good example of disturbed embryonic development of the secondary palate involving insufficient mandibular growth, failed forward tongue movement, and, in the case of a cleft, impeded fusion of the secondary palate. Discussion continues regarding which of the involved pathogenetic factors is the primary cause of the induced cascade of signs: insufficient mandibular growth or failed descent of the tongue.
DESIGN: Forty-five randomly selected, 18-day-old formalin-fixed A/WySn mouse fetuses were investigated. The strain is known to have a basic genetic defect and as much as 44% clefts in the offspring. Twenty-four fetuses in the group had a cleft palate. Mandible position was measured relative to the head and to the presence or absence of a cleft. Cleft width and tongue position were also determined. Thirty-eight NMRI mouse fetuses of the same age served as controls.
RESULTS: All A/WySn fetuses showed marked mandibular retrognathia, which was more severe in the cleft group (p < .05), but there was no correlation between the degree of retrognathia and cleft width. The median cleft width was 3.4 mm (1.6 through 6.3 mm). The tongue was in the cleft in all 12 fetuses with wide clefts (>3.4 mm wide), and free in the oral cavity in the other 12. Tongue position did not influence the degree of retrognathia (p < .05). Moreover, the tongue was free in all fetuses with severe retrognathia.
CONCLUSION: The results support the primary role of retroposition of the mandible in the development of cardinal symptoms of Pierre Robin Sequence.

Entities:  

Mesh:

Year:  2005        PMID: 16001918     DOI: 10.1597/03-166.1

Source DB:  PubMed          Journal:  Cleft Palate Craniofac J        ISSN: 1055-6656


  6 in total

1.  Developmental aspects of the upper airway: report from an NHLBI Workshop, March 5-6, 2009.

Authors:  Carole L Marcus; Richard J H Smith; Leila A Mankarious; Raanan Arens; Gordon S Mitchell; Ravindhra G Elluru; Vito Forte; Steven Goudy; Ethylin W Jabs; Alex A Kane; Eliot Katz; David Paydarfar; Kevin Pereira; Roger H Reeves; Joan T Richtsmeier; Ramon L Ruiz; Bradley T Thach; David E Tunkel; Jeffrey A Whitsett; David Wootton; Carol J Blaisdell
Journal:  Proc Am Thorac Soc       Date:  2009-09-15

2.  Familial dysautonomia model reveals Ikbkap deletion causes apoptosis of Pax3+ progenitors and peripheral neurons.

Authors:  Lynn George; Marta Chaverra; Lindsey Wolfe; Julian Thorne; Mattheson Close-Davis; Amy Eibs; Vickie Riojas; Andrea Grindeland; Miranda Orr; George A Carlson; Frances Lefcort
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-30       Impact factor: 11.205

3.  The canonical Wnt signaling activator, R-spondin2, regulates craniofacial patterning and morphogenesis within the branchial arch through ectodermal-mesenchymal interaction.

Authors:  Yong-Ri Jin; Taryn J Turcotte; Alison L Crocker; Xiang Hua Han; Jeong Kyo Yoon
Journal:  Dev Biol       Date:  2011-01-13       Impact factor: 3.582

Review 4.  Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.

Authors:  Tom B Davidson; Pedro A Sanchez-Lara; Linda M Randolph; Mark D Krieger; Shi-Qi Wu; Ashok Panigrahy; Hiroyuki Shimada; Anat Erdreich-Epstein
Journal:  BMC Med Genet       Date:  2012-03-22       Impact factor: 2.103

Review 5.  Phenotypes, Developmental Basis, and Genetics of Pierre Robin Complex.

Authors:  Susan M Motch Perrine; Meng Wu; Greg Holmes; Bryan C Bjork; Ethylin Wang Jabs; Joan T Richtsmeier
Journal:  J Dev Biol       Date:  2020-12-05

6.  Genetics and management of the patient with orofacial cleft.

Authors:  Luciano Abreu Brito; Joanna Goes Castro Meira; Gerson Shigeru Kobayashi; Maria Rita Passos-Bueno
Journal:  Plast Surg Int       Date:  2012-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.